Correlation Between Mineralys Therapeutics, and Janux Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Janux Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Janux Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mineralys Therapeutics, Common and Janux Therapeutics, you can compare the effects of market volatilities on Mineralys Therapeutics, and Janux Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Janux Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Janux Therapeutics.

Diversification Opportunities for Mineralys Therapeutics, and Janux Therapeutics

0.6
  Correlation Coefficient

Poor diversification

The 3 months correlation between Mineralys and Janux is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Janux Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Janux Therapeutics and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Janux Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Janux Therapeutics has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Janux Therapeutics go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Janux Therapeutics

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to under-perform the Janux Therapeutics. In addition to that, Mineralys Therapeutics, is 2.4 times more volatile than Janux Therapeutics. It trades about -0.09 of its total potential returns per unit of risk. Janux Therapeutics is currently generating about -0.21 per unit of volatility. If you would invest  5,175  in Janux Therapeutics on August 24, 2024 and sell it today you would lose (525.00) from holding Janux Therapeutics or give up 10.14% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Mineralys Therapeutics, Common  vs.  Janux Therapeutics

 Performance 
       Timeline  
Mineralys Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics, is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.
Janux Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Janux Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Janux Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Mineralys Therapeutics, and Janux Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Mineralys Therapeutics, and Janux Therapeutics

The main advantage of trading using opposite Mineralys Therapeutics, and Janux Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Janux Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Janux Therapeutics will offset losses from the drop in Janux Therapeutics' long position.
The idea behind Mineralys Therapeutics, Common and Janux Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Technical Analysis
Check basic technical indicators and analysis based on most latest market data